Drugs suspected to be involved in the DDI-summary
Complete list of drugs taken by the patient
Clinical case description
This is a case of female patient, 55 years old, Caucasian, with no liver and kidney impairment, high 165 cm, weight 88 kg, BMI=32.3 kg/m2 (obese). HIV-1 infection was diagnosed in 2010 and soon after cART was initiated as follows: efavirenz (600 mg QD) + fixed-dose combination of two NRTIs: abacavir (ABC, 600 mg) and lamivudine (3TC,300 mg), achieving undetectable HIV-1 RNA and CD4+ T-cells count above 600 cells/mm3. In 2019, she was diagnosed with metabolic syndrome. Together with cART patient selfprescribed herbal supplement - lemon balm (Melissa officinalis), known as a herbal supplement for the treatment of insulin-resistance and dyslipidemia. She was taking lemon balm tablets 300 mg BID standardized to 7% Rosmarinic acid and 14% Hydroxycinnamic acids. According to the literature review, there were not much data about DDIs in humans on cART and lemon balm. Thus, we performed TDM using validated high-performance liquid chromatography (HPLC) assay and it has shown efavirenz plasma concentration of Ctrough = 1907.349 ng/mL. Pharmacokinetic variability of the nonnucleoside reverse transcriptase inhibitor efavirenz has been documented in the literature and a plasma therapeutic range of 1000–4000 ng/mL has been established for the efavirenz. Thus, we concluded that there is no clinically relevant drug-drug interaction between lemon balm and efavirenz. Furthermore, in the same patient HIV RNA pVL was undetectable.
Despite the lack of information on how Melissa officinalis may interact with antiretroviral drugs, this clinical case suggests no relevant impact of Melissa officinalis on Efavirenz plasma concentrations.